2009-013442-86: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of 48 Weeks of GS-9190 in Combination with Peginterferon Alfa 2a (Pegasys®) and Ribavirin (Copegus®) in Previously Untreated Subjects with Genotype-1 Chronic Hepatitis C Virus (HCV) Infection |
|
|
| Completed | 3 | 18 | Europe | GS-9190, GS-9190, Copegus Tablets 200 mg, Pegasys 180 mcg, Copegus Tablets 200 mg, Pegasys 180 mcg | Gilead Sciences Inc | Chronic Hepatitis C Virus Infection | | 12/10 | | |
